---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-23-036386"
form_type: "8-K"
ticker: "CRDF"
cik: "0001213037"
company_name: "Cardiff Oncology, Inc."
filed_at: "2023-11-02T23:59:59+00:00"
generated_at: "2026-06-08T23:27:33.056207+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Cardiff Oncology shifts lead mCRC program to first-line; Q3 cash $81.4M

## Summary
- Lead onvansertib program advances to first-line RAS-mutated mCRC; Pfizer Ignite to execute Phase 2 CRDF-004 trial.
- FDA agreed on ORR as interim endpoint for accelerated approval; Phase 3 registrational trial planned contingent on CRDF-004.
- mPDAC CRDF-001: ORR 19% (4/21 evaluable) vs historical 7.7%; mPFS 5.0 mo vs 3.1 mo for SoC alone.
- Phase 2 SCLC monotherapy cleared to continue enrollment after safety review of first six patients.
- Cash, equivalents, and short-term investments $81.4M; net cash burn Q3 $8.0M; runway into 2025.

## SEC filing metadata
- accession: 0001628280-23-036386
- form_type: 8-K
- ticker: CRDF
- cik: 0001213037
- company_name: Cardiff Oncology, Inc.
- filed_at: 2023-11-02T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1213037/000162828023036386/0001628280-23-036386-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1213037/000162828023036386/crdf-20231102.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-23-036386
- JSON: https://secwatch.observer/filing/0001628280-23-036386.json
- Plain text: https://secwatch.observer/filing/0001628280-23-036386.txt

## Key facts
- Earnings Releases
  Cardiff Oncology, Inc. reported financial results for third quarter ended September 30, 2023.
  - Period: third quarter ended September 30, 2023
  - Result: reported results
  source text: On November 2, 2023, Cardiff Oncology, Inc. issued a press release announcing company highlights and financial results for the third quarter ended September 30, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1213037/000162828023036386/0001628280-23-036386-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.